New hope for older blood cancer patients: lower-dose combo may reduce transplant complications
NCT ID NCT05622318
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a lower-dose combination of two drugs (PTCy and ruxolitinib) can prevent graft-versus-host disease (GVHD) in older adults receiving a stem cell transplant for blood cancer. About 56 participants will receive the treatment and be monitored for survival without severe GVHD. The goal is to make transplants safer by reducing harmful immune reactions while still controlling the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Frailty check may steer safer cancer care for seniors
- Could gratitude exercises aid blood cancer recovery?
- Can a new tracer light up cancer growth?
- Could a walk a day keep brain fog away after a stem cell transplant?
- Can a cancer drug tame graft-versus-host disease when steroids fail?